Evidence map›Paper›PMID 34152067›Full record

Trial reportJournal of the International AIDS Society2021

Uptake and outcomes of a novel community-based HIV post-exposure prophylaxis (PEP) programme in rural Kenya and Uganda.

James Ayieko, Maya L Petersen, Jane Kabami, Florence Mwangwa, Fred Opel, Marilyn Nyabuti, Edwin D Charlebois, James Peng, Catherine A Koss, Laura B Balzer and 4 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Journal of the International AIDS Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01864603 (Sustainable East Africa Research in Community Health), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01864603 nacompletednot on this map

Sustainable East Africa Research in Community Health

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2021Enrolled150,395ConditionsHIV, Tuberculosis, Hypertension, DiabetesArmsUniversal ART in a streamlined care model, Annual Community Health Campaigns, Targeted PrEP and Targeted testing interventions, Baseline community-based HIV and multi-disease testing
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Observational
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

James AyiekoCenter for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.ORCID 0000-0002-0324-4006
Maya L PetersenDepartment of Biostatistics, University of California, Berkeley, CA, USA.
Jane KabamiInfectious Diseases Research Collaboration, Kampala, Uganda.
Florence MwangwaInfectious Diseases Research Collaboration, Kampala, Uganda.
Fred OpelCenter for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Marilyn NyabutiCenter for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Edwin D CharleboisDepartment of Medicine, University of California, San Francisco, CA, USA.
James PengDepartment of Medicine, University of California, San Francisco, CA, USA.
Catherine A KossDepartment of Medicine, University of California, San Francisco, CA, USA.
Laura B BalzerDepartment of Biostatistics and Epidemiology, University of Massachusetts, Amherst, MA, USA.ORCID 0000-0002-3730-410X
Gabriel ChamieDepartment of Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0002-5860-8081
Elizabeth A BukusiCenter for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Moses R KamyaDepartment of Medicine, Makerere University, Kampala, Uganda.
Diane V HavlirDepartment of Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0003-0761-3136
University of California, San Francisco · USKenya Medical Research Institute · KEInfectious Diseases Research Collaboration · UGMakerere University · UGUniversity of California, Berkeley · USUniversity of Massachusetts Amherst · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)U01AI099959 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2012 to 2016
$39.7M
Optimizing Adherence to PrEP among Young African Women through a Community Adherence Club InterventionK23MH114760 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KOSS, CATHERINE ANNE STIMETS · 2018 to 2021
$796k
NIAID NIH HHS U01 AI099959NIAID NIH HHS UM1 AI068636NIMH NIH HHS K23 MH114760NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

introductionAntiretroviral-based HIV prevention, including pre-exposure prophylaxis (PrEP), is expanding in generalized epidemic settings, but additional prevention options are needed for individuals with periodic, high-risk sexual exposures. Non-occupational post-exposure prophylaxis (PEP) is recommended in global guidelines. However, in Africa, awareness of and access to PEP for sexual exposures are limited. We assessed feasibility, acceptability, uptake and adherence in a pilot study of a patient-centred PEP programme with options for facility- or community-based service delivery.

methodsAfter population-level HIV testing with universal access to PrEP for persons at elevated HIV risk (SEARCH Trial:NCT01864603), we conducted a pilot PEP study in five rural communities in Kenya and Uganda between December 2018 and May 2019. We assessed barriers to PEP in the population and implemented an intervention to address these barriers, building on existing in-country PEP protocols. We used community leaders for sensitization. Test kits and medications were acquired through the Ministry of Health supply chain and healthcare providers based at the Ministry of Health clinics were trained on PEP delivery. Additional intervention components were (a)PEP availability seven days/week, (b)PEP hotline staffed by providers and (c)option for out-of-facility medication delivery. We assessed implementation using the Proctor framework and measured seroconversions via repeat HIV testing. Successful "PEP completion" was defined as self-reported adherence over four weeks of therapy with post-PEP HIV testing.

resultsCommunity leaders were able to sensitize and mobilize for PEP. The Ministry of Health supplied test kits and PEP medications; after training, healthcare providers delivered the 28-day regimen with high completion rates. Among 124 persons who sought PEP, 66% were female, 24% were ≤25 years and 42% were fisherfolk. Of these, 20% reported exposure with a serodifferent partner, 72% with a new or existing relationship and 7% from transactional sex. 12% of all visits were conducted at out-of-facility community-based sites; 35% of participants had ≥1 out-of-facility visit. No serious adverse events were reported. Overall, 85% met the definition of PEP completion. There were no HIV seroconversions.

conclusionsAmong individuals with elevated-risk exposures in rural East African communities, patient-centred PEP was feasible, acceptable and provides a promising addition to the current prevention toolkit.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisFemaleHumansKenyaPilot ProjectsPost-Exposure ProphylaxisRural PopulationUgandaAnti-HIV Agentshigh-risk exposureHIV preventionimplementationpost-exposure prophylaxis (PEP)pre-exposure prophylaxis (PrEP)uptake

Identifiers

PMID34152067
PMCPMC8215805
OpenAlexW3175518744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.